InMed Pharmaceuticals Enters Merger Agreement with Mentari Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: NASDAQ.COM
- Merger Agreement: InMed Pharmaceuticals has entered into a definitive all-stock merger agreement with Mentari Therapeutics, a private biotech firm focused on migraine prevention, marking a strategic consolidation in the biopharmaceutical sector.
- Shareholder Structure Change: Post-merger, existing InMed shareholders are expected to own approximately 1.51% of the combined entity, which is projected to have a pro forma equity value of around $421.4 million, indicating strong market potential.
- Positive Market Reaction: In pre-market trading on NasdaqCM, InMed shares surged by 195% to $2.01, reflecting investor optimism regarding the merger's prospects.
- New Company Operation Model: Upon completion of the merger, the combined entity will operate under the name Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol, enhancing its public market infrastructure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INM
About INM
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE: RAMP) regarding its sale to Publicis Groupe for $38.50 per share, as there may be violations of shareholder rights that investors need to be aware of.
- Merger Impact Analysis: The merger between NextEra Energy, Inc. (NYSE: NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined entity, prompting shareholders to understand the potential implications for their rights.
- Shareholder Rights Protection: InMed Pharmaceuticals, Inc. (NASDAQ: INM) is merging with Mentari Therapeutics, Inc., which is expected to leave InMed shareholders with only about 1.51% ownership in the combined company, highlighting the need for shareholders to be informed about their legal rights.
- Advocacy for Investor Rights: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures to support those affected by securities fraud and corporate misconduct, thereby enhancing investor protection efforts.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between LiveRamp Holdings, Inc. and Publicis Groupe, where LiveRamp shareholders are expected to receive $38.50 per share in cash, potentially providing significant returns for shareholders.
- Merger Transaction Analysis: In the merger between NextEra Energy, Inc. and Dominion Energy, Inc., NextEra shareholders will own approximately 74.5% of the combined company upon closing, demonstrating strong consolidation capabilities in the energy market.
- Share Exchange Proposal: In the NextEra and Dominion transaction, Dominion shareholders are expected to receive 0.8138 shares of NextEra for each share of Dominion, which may impact the long-term interests of shareholders from both companies.
- Emerging Pharma Merger: The merger between InMed Pharmaceuticals, Inc. and Mentari Therapeutics, Inc. is expected to result in InMed shareholders owning approximately 1.51% of the combined company, reflecting integration trends and market potential in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE:RAMP) regarding its sale to Publicis Groupe at $38.50 per share, which may involve potential violations of shareholder rights, prompting shareholders to consider their legal options.
- Merger Impact Analysis: InMed Pharmaceuticals, Inc. (NASDAQ:INM) is merging with Mentari Therapeutics, Inc., with InMed shareholders expected to own approximately 1.51% of the combined entity, a factor that could significantly affect long-term investment returns for shareholders.
- Shareholder Rights Protection: The transaction between Dominion Energy, Inc. (NYSE:D) and NextEra Energy, Inc. involves an exchange of 0.8138 shares of NextEra for each share of Dominion, and Halper Sadeh LLC may seek to negotiate increased consideration and additional disclosures to safeguard shareholder interests.
- Post-Merger Equity Structure: The merger between NextEra Energy, Inc. (NYSE:NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined company, necessitating shareholder awareness of the potential impacts on their equity value post-merger.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating the transaction between Dominion Energy, Inc. and NextEra Energy, Inc., which involves exchanging 0.8138 shares of NextEra for each share of Dominion, potentially limiting superior competing offers.
- Shareholder Rights Protection: AvalonBay Communities, Inc. shareholders will receive 2.793 shares of Equity Residential common stock for each share of AvalonBay, and Halper Sadeh LLC encourages shareholders to understand their legal rights and options to protect their interests.
- Merger Transaction Impact: The merger between InMed Pharmaceuticals, Inc. and Mentari Therapeutics, Inc. is expected to result in InMed shareholders owning approximately 1.51% of the combined company, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Maintenance: The merger between Equity Residential and AvalonBay Communities, Inc. will result in Equity Residential shareholders owning about 48.8% of the combined company, with Halper Sadeh LLC representing shareholders to seek additional disclosures and remedies.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Investigation into InMed Pharmaceuticals Board's Actions
- Board Investigation: The law firm Brodsky & Smith is investigating potential breaches of fiduciary duty by the InMed Pharmaceuticals Board in connection with the sale to Mentari Therapeutics, which may affect shareholder rights.
- Impact on Shareholder Value: InMed shareholders are expected to own only about 1.51% of the combined entity, raising concerns about the fairness of the transaction and potentially leading to significant value loss for shareholders.
- Legal Consultation Offered: Brodsky & Smith is offering legal consultations to assist InMed shareholders in understanding the legal ramifications of the investigation, ensuring that shareholders are protected in the transaction.
- Extensive Litigation Experience: The firm has a strong track record in securities and class action lawsuits, having successfully recovered millions for clients, demonstrating its commitment and capability in safeguarding shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE: RAMP) regarding its sale to Publicis Groupe for $38.50 per share, as there may be violations of shareholder rights that investors need to be aware of.
- Merger Impact Analysis: The merger between NextEra Energy, Inc. (NYSE: NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined entity, prompting shareholders to understand the potential implications for their rights.
- Shareholder Rights Protection: InMed Pharmaceuticals, Inc. (NASDAQ: INM) is merging with Mentari Therapeutics, Inc., which is expected to leave InMed shareholders with only about 1.51% ownership in the combined company, highlighting the need for shareholders to be informed about their legal rights.
- Advocacy for Investor Rights: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures to support those affected by securities fraud and corporate misconduct, thereby enhancing investor protection efforts.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between LiveRamp Holdings, Inc. and Publicis Groupe, where LiveRamp shareholders are expected to receive $38.50 per share in cash, potentially providing significant returns for shareholders.
- Merger Transaction Analysis: In the merger between NextEra Energy, Inc. and Dominion Energy, Inc., NextEra shareholders will own approximately 74.5% of the combined company upon closing, demonstrating strong consolidation capabilities in the energy market.
- Share Exchange Proposal: In the NextEra and Dominion transaction, Dominion shareholders are expected to receive 0.8138 shares of NextEra for each share of Dominion, which may impact the long-term interests of shareholders from both companies.
- Emerging Pharma Merger: The merger between InMed Pharmaceuticals, Inc. and Mentari Therapeutics, Inc. is expected to result in InMed shareholders owning approximately 1.51% of the combined company, reflecting integration trends and market potential in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE:RAMP) regarding its sale to Publicis Groupe at $38.50 per share, which may involve potential violations of shareholder rights, prompting shareholders to consider their legal options.
- Merger Impact Analysis: InMed Pharmaceuticals, Inc. (NASDAQ:INM) is merging with Mentari Therapeutics, Inc., with InMed shareholders expected to own approximately 1.51% of the combined entity, a factor that could significantly affect long-term investment returns for shareholders.
- Shareholder Rights Protection: The transaction between Dominion Energy, Inc. (NYSE:D) and NextEra Energy, Inc. involves an exchange of 0.8138 shares of NextEra for each share of Dominion, and Halper Sadeh LLC may seek to negotiate increased consideration and additional disclosures to safeguard shareholder interests.
- Post-Merger Equity Structure: The merger between NextEra Energy, Inc. (NYSE:NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined company, necessitating shareholder awareness of the potential impacts on their equity value post-merger.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating the transaction between Dominion Energy, Inc. and NextEra Energy, Inc., which involves exchanging 0.8138 shares of NextEra for each share of Dominion, potentially limiting superior competing offers.
- Shareholder Rights Protection: AvalonBay Communities, Inc. shareholders will receive 2.793 shares of Equity Residential common stock for each share of AvalonBay, and Halper Sadeh LLC encourages shareholders to understand their legal rights and options to protect their interests.
- Merger Transaction Impact: The merger between InMed Pharmaceuticals, Inc. and Mentari Therapeutics, Inc. is expected to result in InMed shareholders owning approximately 1.51% of the combined company, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Maintenance: The merger between Equity Residential and AvalonBay Communities, Inc. will result in Equity Residential shareholders owning about 48.8% of the combined company, with Halper Sadeh LLC representing shareholders to seek additional disclosures and remedies.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Investigation into InMed Pharmaceuticals Board's Actions
- Board Investigation: The law firm Brodsky & Smith is investigating potential breaches of fiduciary duty by the InMed Pharmaceuticals Board in connection with the sale to Mentari Therapeutics, which may affect shareholder rights.
- Impact on Shareholder Value: InMed shareholders are expected to own only about 1.51% of the combined entity, raising concerns about the fairness of the transaction and potentially leading to significant value loss for shareholders.
- Legal Consultation Offered: Brodsky & Smith is offering legal consultations to assist InMed shareholders in understanding the legal ramifications of the investigation, ensuring that shareholders are protected in the transaction.
- Extensive Litigation Experience: The firm has a strong track record in securities and class action lawsuits, having successfully recovered millions for clients, demonstrating its commitment and capability in safeguarding shareholder interests.
See More
